What is LOPJLB’s current signal on IRLA?

LOPJLB’s latest quantitative signal on IRulya Therapeutics Inc. (IRLA) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is IRLA in?

IRulya Therapeutics Inc. (IRLA) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does IRulya Therapeutics Inc. (IRLA) do?

IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

IRulya Therapeutics Inc. (IRLA)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$30.00+7.64%Close

SELLRECOVERY · day 5

[SCORES & PROFILE]

FUND: 10
VALUE: 14
GROWTH: 39
GARP: 0
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-248.0%

REV YoY-

ROE-413.3%

EPS YoY-

ROA-74.6%

GROSS

NET

[VALUATION]

P/E TTM-0.44

P/E FWD-

SECTOR PE20.48

INDUSTRY PE13.99

P/B1.70

P/FCF-

EV/EBITDA1.18

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E-

ALTMAN Z-

CURR RATIO14.52

ND/EBITDA-

BETA1.33

FAQ

What is LOPJLB’s current signal on IRLA?: LOPJLB’s latest quantitative signal on IRulya Therapeutics Inc. (IRLA) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is IRLA in?: IRulya Therapeutics Inc. (IRLA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does IRulya Therapeutics Inc. (IRLA) do?: IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

IRulya Therapeutics Inc. (IRLA)

Key stats

Prediction markets

FUNDAMENTALS

Company news

FAQ